Skip to main content
SpringerLink
Log in

A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome

  • Clinical Experiences
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective: To evaluate the clinical effect and safety of Safflower Yellow injection (SYI) in treating coronary heart disease angina pectoris (CHD-AP) with Xin-blood stagnation syndrome (XBSS).Methods: Adopted was the multi-centered, randomized, positive parallel controlled method, 448 patients with CHD-AP-XBSS were enrolled and divided into two groups, 336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days, so as to observe the conditions of angina, electrocardiogram, and therapeutic effect on traditinal Chinese medicine (TCM) symptoms as well as the safety of the treatment.Results: The significantly effective rate and total effective rate in the tested group were 60.06% (194/323) and 91.02% (294/323) respectively; those in improvement of TCM symptoms were 40.18% (129/321) and 75. 23% (243/323) respectively, which were better than those in the control group (P<0.01).Conclusion: SYI Injection is effective and safe in treating CHD-AP-XBSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zheng XY. Guiding principle of clinical research on Chinese new drugs. 1st ed. Beijing: Chinese Publishing of Medical and Pharmaceutical Technique, 2002: 69–73.

    Google Scholar 

  2. Special Group of Clinical Nomenclature Standardization, International Association of Heart Diseases and WHO. Standard for nomenclature and diagnosis of ischemic heart disease. Chin J Cardiol 1981; 9(1): 75–76.

    Google Scholar 

  3. National Administration of Drugs Supervising and Managing. Technologic requirement for research of Chinese new drugs. 2000: 29–30.

  4. Zheng QS, Sun RY, Chen ZY. Safety analysis on the regulation of minimal cases in clinical trial of new drugs. Chin J Clin Pharmacol Ther 2003; 8 (3): 354–355.

    Google Scholar 

  5. Zheng QS, Sun RY, Chen ZY. Discussion on the concise calculation and equivalent standard for sample assessment in new drug clinical trial. Chin New Drug J 2003;12 (5): 368–371.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The National Clinical Base of Drug Research, Xiyuan Hospital, China Academy of Traditional Chinese Medicine, 100091, Beijing

    Zhang Qiong

  2. Deyuantang Pharmaceutical Ltd. Co., Shangxi

    Peng Jian-hua

  3. People’s Hospital of Qingdao, China

    Zhang Xiang-nong

Authors
  1. Zhang Qiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peng Jian-hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhang Xiang-nong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhang Qiong.

Additional information

Supported by the National High Technology Research and Development Program of China (863 Program), No. 2004AA2Z3692

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qiong, Z., Jian-hua, P. & Xiang-nong, Z. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome. Chin. J. Integr. Med. 11, 222–225 (2005). https://doi.org/10.1007/BF02836509

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02836509

Key words

Search

Navigation